Desidustat (INN, also known as ZYAN1) is a drug for the treatment of anemia of chronic kidney disease.

This drug with the brand name Oxemia is discovered and developed by Zydus Life Sciences.

[2] Clinical trials on desidustat have been done in India and Australia.

[4] The subject expert committee of CDSCO has recommended the grant of permission for manufacturing and marketing of Desidustat 25 mg and 50 mg tablets in India, based on some conditions related to package insert, phase 4 protocols, prescription details, and GCP.

[5] Zydus Lifesciences and Sun Pharmaceuticals have entered an agreement in October 2023 to co-market Desidustat.